Delving into the Latest Updates on Traneurocin with Synapse

Overview

Drug Type

Small molecule drug

Synonyms

NEUROSIVIR, N-831, NA 831

+ [2]

Target-

Mechanism

Neurogenesis stimulants

Therapeutic Areas

Active Indication

Inactive Indication

Originator Organization

Active Organization

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	US	NeuroActiva, Inc.	08 Aug 2022
Severe acute respiratory infection	Phase 3	US	NeuroActiva, Inc.	15 Jun 2022
COVID-19	Phase 3	US	NeuroActiva, Inc.	01 Nov 2020
COVID-19	Phase 3	NZ	NeuroActiva, Inc.	01 Nov 2020
Severe Acute Respiratory Syndrome	Phase 3	US	NeuroActiva, Inc.	01 Nov 2020
Severe Acute Respiratory Syndrome	Phase 3	NZ	NeuroActiva, Inc.	01 Nov 2020
Dementia, Vascular	Phase 2	NZ	NeuroActiva, Inc.	15 Sep 2018
Lewy Body Disease	Phase 2	NZ	NeuroActiva, Inc.	15 Sep 2018
Mild cognitive disorder	Phase 2	NZ	NeuroActiva, Inc.	15 Sep 2018
Nerve Degeneration	Phase 1	US	NeuroActiva, Inc.	15 Sep 2020

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03538522 (AAIC 12022 \| AAIC 22022) Manual	Phase 2	Alzheimer Disease	56	Traneurocin	vdrxpbqcpc(nitelzifcd) = NA-831 was well-tolerated at 30 mg/day for 24 weeks, and no serious adverse events were observed. cucxfasjut (mixoguwadr ) View more	Positive	20 Dec 2022
				Placebo
CTAD2022	Phase 2	-	56	NA-831 30 mg	ixaasgtjyn(rlxkgyotzl) = avqtkpgmma qvzxxaitpw (leqskzzjpm )	-	03 Dec 2022
AAIC2018	Not Applicable	Alzheimer Disease	32	Placebo	aqejtwvzcz(jogbwrfpvy) = koywxjkssl qpnftlepfs (gdiejvaiju )	-	01 Jul 2018
				NA-831 5 mg	aqejtwvzcz(jogbwrfpvy) = qvzwtsxesk qpnftlepfs (gdiejvaiju )